-
1.发明申请公开(公告)号：US20080274055A1
公开(公告)日：2008-11-06
申请号：US11813092
申请日：2005-12-30
IPC分类号： A61K39/395 , C07K16/30 , G01N33/574 , A61K49/00 , C12N15/13 , C12N15/79 , C12N5/10 , A61P35/00
CPC分类号： C07K16/3007 , A61K2039/505 , C07K2317/24 , C07K2317/565
摘要： The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.
摘要翻译： 本公开提供与亲本抗体相比保留CEA结合亲和力的人源化COL-1单克隆抗体。 本文还公开了与亲本抗体相比具有降低的免疫原性的人源化COL-1单克隆抗体。 公开的人源化COL-1抗体包括用来自同源人序列的相应位置的残基取代框架残基。 在几个实施方案中，公开了在检测或治疗受试者中表达CEA的肿瘤或细胞的情况下使用人源化COL-1抗体的方法。 还公开了包含本文所述的人源化COL-1抗体的试剂盒。
-
2.发明授权公开(公告)号：US08828717B2
公开(公告)日：2014-09-09
申请号：US12946381
申请日：2010-11-15
发明人： Syed Kashmiri , Jeffrey Schlom , Eduardo A. Padlan
CPC分类号： C07K16/3007 , A61K2039/505 , C07K2317/24 , C07K2317/565
摘要： The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.
摘要翻译： 本公开提供与亲本抗体相比保留CEA结合亲和力的人源化COL-1单克隆抗体。 本文还公开了与亲本抗体相比具有降低的免疫原性的人源化COL-1单克隆抗体。 公开的人源化COL-1抗体包括用来自同源人序列的相应位置的残基取代框架残基。 在几个实施方案中，公开了使用人源化COL-1抗体检测或治疗受试者中表达CEA的肿瘤或细胞的方法。 还公开了包含本文所述的人源化COL-1抗体的试剂盒。
-
3.发明授权公开(公告)号：US07855276B2
公开(公告)日：2010-12-21
申请号：US11813092
申请日：2005-12-30
发明人： Syed Kasmiri , Jeffrey Schlom , Eduardo A. Padlan
IPC分类号： C12P21/08 , C07K16/00 , A61K39/395 , A61K39/00 , G01N33/53
CPC分类号： C07K16/3007 , A61K2039/505 , C07K2317/24 , C07K2317/565
摘要： The present disclosure provides humanized COL-1 monoclonal antibodies that retain CEA binding affinity, compared to a parent antibody. Also disclosed herein are humanized COL-1 monoclonal antibodies that have reduced immunogenicity, compared to a parent antibody. The disclosed humanized COL-1 antibodies include substitution of framework residues with residues from the corresponding positions of a homologous human sequence. In several embodiments, methods are disclosed for the use of a humanized COL-1 antibody in the detection or treatment of a CEA-expressing tumor or cell in a subject. Also disclosed is a kit including the humanized COL-1 antibodies described herein.
摘要翻译： 本公开提供与亲本抗体相比保留CEA结合亲和力的人源化COL-1单克隆抗体。 本文还公开了与亲本抗体相比具有降低的免疫原性的人源化COL-1单克隆抗体。 公开的人源化COL-1抗体包括用来自同源人序列的相应位置的残基取代框架残基。 在几个实施方案中，公开了使用人源化COL-1抗体检测或治疗受试者中表达CEA的肿瘤或细胞的方法。 还公开了包含本文所述的人源化COL-1抗体的试剂盒。
-
公开(公告)号：US20100303720A1
公开(公告)日：2010-12-02
申请号：US12819920
申请日：2010-06-21
IPC分类号： A61K51/10 , A61K39/395 , A61P35/00
CPC分类号： A61K49/0002 , A61K38/00 , A61K51/1045 , A61K2039/505 , C07K16/30 , C07K16/3046 , C07K16/4208 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2799/026 , G01N33/5743
摘要： The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity DeterminingRegions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.
摘要翻译： 本发明针对具有最小鼠含量的CC49单克隆抗体的小鼠 - 人嵌合变体。 本发明的第一方面提供了存在CC49的全部六（三个重链和三个轻链）互补决定区（CDR）的人源化单克隆抗体（HuCC49）的CDR变体。 本发明的第二方面提供了仅存在来自CC49的至少一个CDR的特异性确定区（SDR）的人源化单克隆抗体（HuCC49）的SDR变体。 本发明还涉及制备使用变体的变体和治疗方法的生物技术方法。
-
5.发明申请METHODS TO DETERMINE IMMUNOGENICITY OF HUMANIZED ANTI-TAG 72 CC49 ANTIBODIES 失效确定人类抗体72 CC49抗体的免疫原性的方法公开(公告)号：US20110159525A1
公开(公告)日：2011-06-30
申请号：US13039171
申请日：2011-03-02
CPC分类号： C07K16/30 , A61K51/1045 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/622 , C07K2317/92
摘要： The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody.
摘要翻译： 本公开提供以高结合亲和力结合TAG-72并且是免疫原性最小的人源化CC49单克隆抗体。 在一个实施方案中，人源化CC49抗体包括CC49抗体的轻链互补决定区3中的非保守氨基酸取代。 在另一个实施方案中，人源化CC49抗体包括轻链互补决定区3中的第一残基的非保守取代和人源化CC49抗体的互补决定区的第二残基的取代。 在几个实施方案中，公开了使用人源化CC49抗体的方法。
-
公开(公告)号：US07763719B2
公开(公告)日：2010-07-27
申请号：US11776437
申请日：2007-07-11
IPC分类号： C07H21/04
CPC分类号： A61K49/0002 , A61K38/00 , A61K51/1045 , A61K2039/505 , C07K16/30 , C07K16/3046 , C07K16/4208 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2799/026 , G01N33/5743
摘要： The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.
摘要翻译： 本发明针对具有最小鼠含量的CC49单克隆抗体的小鼠 - 人嵌合变体。 本发明的第一方面提供了存在CC49的全部六（三个重链和三个轻链）互补决定区（CDR）的人源化单克隆抗体（HuCC49）的CDR变体。 本发明的第二方面提供了仅存在来自CC49的至少一个CDR的特异性确定区（SDR）的人源化单克隆抗体（HuCC49）的SDR变体。 本发明还涉及制备使用变体的变体和治疗方法的生物技术方法。
-
7.发明申请公开(公告)号：US20090317903A1
公开(公告)日：2009-12-24
申请号：US12474221
申请日：2009-05-28
CPC分类号： C07K16/30 , A61K51/1045 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/622 , C07K2317/92
摘要： The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.
摘要翻译： 本公开提供以高结合亲和力结合TAG-72并且是免疫原性最小的人源化CC49单克隆抗体。 在一个实施方案中，人源化CC49抗体包括CC49抗体的轻链互补决定区3中的非保守氨基酸取代。 在另一个实施方案中，人源化CC49抗体包括轻链互补决定区3中的第一残基的非保守取代和人源化CC49抗体的互补决定区的第二残基的取代。 在几个实施方案中，公开了使用人源化CC49抗体检测或治疗受试者的肿瘤的方法。 还公开了包含本文所述的人源化CC49抗体的试剂盒。
-
公开(公告)号：US07256004B2
公开(公告)日：2007-08-14
申请号：US10927433
申请日：2004-08-25
IPC分类号： G01N33/53
CPC分类号： A61K49/0002 , A61K38/00 , A61K51/1045 , A61K2039/505 , C07K16/30 , C07K16/3046 , C07K16/4208 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N2799/026 , G01N33/5743
摘要： The invention is directed towards mouse-human chimeric variants of CC49 monoclonal antibodies with minimal murine content. A first aspect of the invention provides CDR variants of humanized monoclonal antibody (HuCC49) in which less than all six (three heavy chain and three light chain) Complementarity Determining Regions (CDRs) of CC49 are present. A second aspect of the invention provides SDR variants of humanized monoclonal antibody (HuCC49) in which only Specificity Determining Regions (SDRs) of at least one CDR from CC49 are present. The invention is also directed towards biotechnological methods of making the variants and therapeutic methods of using the variants.
摘要翻译： 本发明针对具有最小鼠含量的CC49单克隆抗体的小鼠 - 人嵌合变体。 本发明的第一方面提供了存在CC49的全部六（三个重链和三个轻链）互补决定区（CDR）的人源化单克隆抗体（HuCC49）的CDR变体。 本发明的第二方面提供了仅存在来自CC49的至少一个CDR的特异性确定区（SDR）的人源化单克隆抗体（HuCC49）的SDR变体。 本发明还涉及制备使用变体的变体和治疗方法的生物技术方法。
-
9.发明授权Methods to determine immunogenicity of humanized anti-tag 72 CC49 antibodies 失效确定人源化抗标签72 CC49抗体免疫原性的方法公开(公告)号：US08535890B2
公开(公告)日：2013-09-17
申请号：US13039171
申请日：2011-03-02
IPC分类号： G01N33/53
CPC分类号： C07K16/30 , A61K51/1045 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/622 , C07K2317/92
摘要： The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody.
摘要翻译： 本公开提供以高结合亲和力结合TAG-72并且是免疫原性最小的人源化CC49单克隆抗体。 在一个实施方案中，人源化CC49抗体包括CC49抗体的轻链互补决定区3中的非保守氨基酸取代。 在另一个实施方案中，人源化CC49抗体包括轻链互补决定区3中的第一残基的非保守取代和人源化CC49抗体的互补决定区的第二残基的取代。 在几个实施方案中，公开了使用人源化CC49抗体的方法。
-
公开(公告)号：US07919607B2
公开(公告)日：2011-04-05
申请号：US12474221
申请日：2009-05-28
CPC分类号： C07K16/30 , A61K51/1045 , A61K2039/505 , C07K2317/24 , C07K2317/55 , C07K2317/622 , C07K2317/92
摘要： The present disclosure provides humanized CC49 monoclonal antibodies that bind TAG-72 with high binding affinity and that are minimally immunogenic. In one embodiment, a humanized CC49 antibody includes a non-conservative amino acid substitution in a light chain complementarity determining region 3 of the CC49 antibody. In a further embodiment, the humanized CC49 antibody includes a non-conservative substitution of a first residue in a light chain complementarity determining region 3 and a substitution of a second residue in a complementarity determining region of the humanized CC49 antibody. In several of the embodiments, methods are disclosed for the use of a humanized CC49 antibody in the detection or treatment of a tumor in a subject. Also disclosed is a kit including the humanized CC49 antibody described herein.
摘要翻译： 本公开提供以高结合亲和力结合TAG-72并且是免疫原性最小的人源化CC49单克隆抗体。 在一个实施方案中，人源化CC49抗体包括CC49抗体的轻链互补决定区3中的非保守氨基酸取代。 在另一个实施方案中，人源化CC49抗体包括轻链互补决定区3中的第一残基的非保守取代和人源化CC49抗体的互补决定区的第二残基的取代。 在几个实施方案中，公开了使用人源化CC49抗体检测或治疗受试者的肿瘤的方法。 还公开了包含本文所述的人源化CC49抗体的试剂盒。
-
-
-
-
-
-
-
-
-
搜索结果
32 条记录 (耗时 0.036 秒)